The acquisition of New River Pharmaceuticals Inc. will allow Shire pic to capture the full economic value of Vyvanse,a breakthrough attention deficit and hyperactivity disorder drug, and to gain control of the future development and commercialization of the product. FDA approved Vyvanse in February.Shire will acquire New River (nrpharma. com) for dollar64 per share, or about dollar2.6 billion in total, in an all-cash transaction unanimously recommended by the boards of both companies. The acquisition is structured as a tender offer for all outstanding shares of New River followed by a merger.
展开▼
机译：收购New River Pharmaceuticals Inc.将使Shire pic能够获得Vyvanse的全部经济价值，Vyvanse是一种突破性的注意力缺陷和多动症药物，并可以控制该产品的未来开发和商业化。 FDA于2月批准了Vyvanse。Shire将以每股64美元（合计约26亿美元）的价格收购New River（nrpharma.com），这是两家公司董事会一致建议的全现金交易。此次收购是要约收购New River的所有流通股，然后是合并。
展开▼
